XML 30 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition
 9 Months Ended
Sep. 30, 2020
Revenue Recognition [Abstract]  
Revenue Recognition

9. Revenue Recognition

Our product revenue, net consisted of the following:

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

HEPLISAV-B

 

$

11,599

 

 

$

10,158

 

 

$

24,518

 

 

$

24,086

 

CpG 1018

 

 

1,677

 

 

 

-

 

 

 

1,677

 

 

 

-

 

Total

 

$

13,276

 

 

$

10,158

 

 

$

26,195

 

 

$

24,086

 

 

All of our HEPLISAV-B sales were in the U.S. For the nine months ended September 30, 2020 and 2019, our three largest Customers collectively represented approximately 68% and 63% of our HEPLISAV-B product revenue, respectively. All of our CpG 1018 sales were outside the U.S.

The following table summarizes balances and activity in HEPLISAV-B product revenue allowance and reserve categories for the nine months ended September 30, 2020 (in thousands):

 

 

 

Balance at

Beginning

of Period

 

 

Provisions

related to

current

period sales

 

 

Credit or

payments

made during

the period

 

 

Balance

at End of

Period

 

Nine months ended September 30, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable reserves(1)

 

$

2,701

 

 

$

8,806

 

 

$

(7,945

)

 

$

3,562

 

Revenue reserve accruals(2)

 

$

3,893

 

 

$

5,029

 

 

$

(3,240

)

 

$

5,682

 

 

(1)

Reserves are for chargebacks, discounts and other fees.

(2)

Accruals are for returns, rebates and other fees.